Permanently Lift Restrictions on the Abortion Pill!
We’re calling on the FDA to let pregnant people receive the abortion pill through the mail so that they can get the pill where they take the pill — at home!
FDA Comments- Makena
[FDA-2019-N-4203] To Whom It May Concern: The National Women’s Health Network (NWHN) is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and by choice, we do not accept financial support from drug companies or medical device manufacturers. We bring the voices, concerns and needs of women consumers to policy and regulatory tables. The NWHN encourages the Food and Drug…
Consumer Health Info: Addyi Health
Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.
The NWHN’s Statement on the FDA Ordering Manufacturers of Surgical Mesh to Stop Selling Devices for Uterine Prolapse
The National Women's Health Network has a long history of raising concerns to the FDA asking them to reclassify surgical mesh for pelvic organ prolapse (POP) repair from a Class II to Class III medical device.
The NWHN’s Statement on the FDA Ordering Sprout Pharmaceuticals to Retain Black Box Label Warning Women Not Mix Addyi and Alcohol
FOR IMMEDIATE RELEASE Contact: Evita Almassi, [email protected] or (202) 682-6240
FDA Meeting – Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse
Testimony regarding surgical mesh and pelvic organ prolapse, delivered at the meeting of the FDA obstetrics and gynecology devices panel.
Generic vs. Brand Name Prescription Drugs
What's the difference between generic and brand-name prescription drugs?
Your Generic Drug Label Doesn’t Tell You EVERYTHING
Last week we attended a public meeting at the Food and Drug Administration (FDA) where we testified in front of supporters and opponents on behalf of the FDA’s proposed rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products.
FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder